Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China flag China · Delayed Price · Currency is CNY
11.90
+0.06 (0.51%)
Feb 3, 2026, 1:25 PM CST

SHE:002399 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
5,3845,2595,4317,0976,3185,284
Other Revenue
---61.9247.3348.04
5,3845,2595,4317,1596,3655,332
Revenue Growth (YoY)
-0.96%-3.17%-24.14%12.48%19.38%15.30%
Cost of Revenue
3,6743,5204,4904,8614,3673,300
Gross Profit
1,7111,739940.92,2981,9982,032
Selling, General & Admin
1,0331,0281,192975.69850.68821.65
Research & Development
45.85--252.14221.1160.01
Other Operating Expenses
1.75-26.66-34.4922.7320.9626.07
Operating Expenses
1,085993.51,1581,2991,1651,018
Operating Income
625.55745.82-217.29998.55833.531,014
Interest Expense
-377.17-141.19-223.22-235.24-201.63-247.72
Interest & Investment Income
-104.275.9554.1454.86301.79
Earnings From Equity Investments
-141.82-141.82-447.95---
Currency Exchange Gain (Loss)
-12.84-12.8485.87186.33-205.04-248.83
Other Non Operating Income (Expenses)
133.9-72.08-30.71-32.55-46.18-30.47
EBT Excluding Unusual Items
227.62482.09-757.34971.23435.53788.38
Impairment of Goodwill
---68.16---
Gain (Loss) on Sale of Investments
401.06315.0716.2-176.91-226.82494.45
Gain (Loss) on Sale of Assets
1.72---2.76-5.10.38
Asset Writedown
-142.34-55.37-44.52-0.42-1.1-0.24
Other Unusual Items
-7.43-15.56-74.5238.7119.7544.87
Pretax Income
480.63726.23-928.33829.85222.261,328
Income Tax Expense
82.15101.31-126.18114.82-11.12306.2
Earnings From Continuing Operations
398.48624.92-802.16715.04233.381,022
Minority Interest in Earnings
21.7221.8218.912.397.42.58
Net Income
420.2646.74-783.26727.43240.791,024
Net Income to Common
420.2646.74-783.26727.43240.791,024
Net Income Growth
---202.10%-76.49%-3.32%
Shares Outstanding (Basic)
1,4701,4701,4781,4681,4671,353
Shares Outstanding (Diluted)
1,4701,4701,4781,4681,4671,353
Shares Change (YoY)
-0.56%-0.54%0.67%0.05%8.42%8.51%
EPS (Basic)
0.290.44-0.530.500.160.76
EPS (Diluted)
0.290.44-0.530.500.160.76
EPS Growth
---201.95%-78.32%-10.90%
Free Cash Flow
1,6891,995-39.22-979.03-200.49-175.21
Free Cash Flow Per Share
1.151.36-0.03-0.67-0.14-0.13
Dividend Per Share
0.2500.250-0.1000.0350.150
Dividend Growth
---185.71%-76.67%-16.67%
Gross Margin
31.77%33.07%17.32%32.10%31.39%38.11%
Operating Margin
11.62%14.18%-4.00%13.95%13.10%19.01%
Profit Margin
7.80%12.30%-14.42%10.16%3.78%19.21%
Free Cash Flow Margin
31.37%37.93%-0.72%-13.68%-3.15%-3.29%
EBITDA
875.311,027105.611,2721,1031,287
EBITDA Margin
16.26%19.53%1.94%17.77%17.34%24.14%
D&A For EBITDA
249.77281.11322.89273.87269.92273.73
EBIT
625.55745.82-217.29998.55833.531,014
EBIT Margin
11.62%14.18%-4.00%13.95%13.10%19.01%
Effective Tax Rate
17.09%13.95%-13.84%-23.06%
Revenue as Reported
125.54--7,1596,3655,332
Advertising Expenses
---23.218.0411.66
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.